About: Big pharma

Health 12-03-2021

Covid-19 vaccine: A shot at redemption for Johnson and Johnson?

US health care giant Johnson & Johnson, beset by recent scandals over talcum powder and the opioid crisis, is poised for a reputational lift with its pathbreaking coronavirus vaccine.
Economy & Jobs 11-03-2021

Rich countries block push by developing nations to waive COVID vaccine patents rights

Richer members of the World Trade Organization (WTO) blocked a push by over 80 developing countries on Wednesday (10 March) to waive patent rights in an effort to boost production of COVID-19 vaccines for poor nations.
Coronavirus 26-02-2021

EU leaders take baby step toward vaccination certificate, fume at pharma industry

EU leaders decided at a teleconference on Thursday (25 February) to start working on a digital vaccination certificate now and start implementing it when there is sufficient number of EU citizens vaccinated.
Coronavirus 08-02-2021

Patents are not an obstacle to ramp up COVID-19 vaccines production, EU says

The European Commission aims to ramp up production of COVID-19 vaccines through “voluntary” sharing of know-how among pharma companies, EU sources said, emphasising that patents are not an obstacle to do that.
Health 05-02-2021

Countdown to ‘catastrophe’: How the EU fight for COVID shots unfolded

This Reuters report is based on exclusive details of internal EU talks over the past month in diplomatic notes, and interviews of four people present at key meetings to verify them.
Health 24-11-2020

EU leaked pharma strategy pushes innovation for a resilient Europe

Affordability, availability and sustainability are the main focus points of the EU’s new pharmaceutical strategy, due to be published on Wednesday (25 November). 
Health 09-07-2020

MEP: A common EU tool to incentivise production and availability of orphan drugs

When it comes to rare diseases and 'orphan drugs', technology is there to support an “objective” EU tool that could provide the pharma industry with the necessary incentives to research and produce orphan drugs and simultaneously avoid exhausting ailing health systems, MEP Stelios Kympouropoulos told EURACTIV in an interview.
Health 08-07-2020

EU orphan drugs law and the emergence of SMEs

The legal framework provided by the current EU orphan drugs regulation has encouraged a number of small and medium sized companies (SMEs) to develop innovative technologies in the fight against rare diseases in Europe, stakeholders told EURACTIV.com.
Health 06-07-2020

Commission’s ‘risky’ move to re-visit orphan drugs regulation

The European Commission is expected to present by the end of July an evaluation study on the pros and cons of the application of orphan and paediatric regulations, which deal with a niche segment of rare diseases that affect fewer than five in 10,000 people.
Future EU 23-06-2020

German EU Presidency: Influenced by lobbyists?

Large lobbying associations have a strong influence on the German government and there are concerns that this might impact its EU Council presidency, which starts on 1 July, warned a study conducted by NGOs LobbyControl and Corporate Europe Observatory. EURACTIV Germany reports.
Economy & Jobs 19-09-2018

Drug industry reacts to Oxfam’s allegations of tax-dodging

Four of the world’s biggest pharma companies appear to hide their profits in tax havens, according to a report published by Oxfam on Tuesday (18 September). Businesses said they are in the clear.
Health 22-02-2018

Health care risks being forgotten in Brexit talks, industry warns

Health risks being forgotten in Brexit negotiations, potentially delaying the availability of new medicines and imposing large costs on manufacturers, public health leaders have warned.
Brexit 26-04-2017

Drugs firms call for phased transition of regulation after Brexit

Pharmaceutical companies called on Thursday (27 April) for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.
Health 29-09-2016

Fake drugs cost EU billions of euros, its health and its jobs

Counterfeit drugs are not only hazardous to health, they cost people their jobs too, a new EU study has revealed. But Germans in particular are willing to take risks. EURACTIV's partner Der Tagesspiegel reports.